PMC:7784830 / 22222-24720 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"398","span":{"begin":684,"end":688},"obj":"Species"},{"id":"399","span":{"begin":990,"end":1001},"obj":"Species"},{"id":"400","span":{"begin":1567,"end":1579},"obj":"Species"},{"id":"401","span":{"begin":1644,"end":1658},"obj":"Species"},{"id":"402","span":{"begin":1884,"end":1916},"obj":"Disease"},{"id":"403","span":{"begin":1918,"end":1922},"obj":"Disease"}],"attributes":[{"id":"A398","pred":"tao:has_database_id","subj":"398","obj":"Tax:2697049"},{"id":"A399","pred":"tao:has_database_id","subj":"399","obj":"Tax:11118"},{"id":"A400","pred":"tao:has_database_id","subj":"400","obj":"Tax:11118"},{"id":"A401","pred":"tao:has_database_id","subj":"401","obj":"Tax:397342"},{"id":"A402","pred":"tao:has_database_id","subj":"402","obj":"MESH:D018352"},{"id":"A403","pred":"tao:has_database_id","subj":"403","obj":"MESH:D018352"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Name of the player Details of antiviral vaccines under development Ref.\nMigal Galilee Research Institute, Israel Developing an oral (mucosal) vaccine, wherein the viral antigen is delivered via mucosa tissues by self-activated endocytosis [104]\nEntos Pharmaceuticals Fusogenix – DNA vaccine is being developed based on its patent protected platform, proteo-lipid vehicle (PLV). It uses a new mechanism for delivering genetic material into the cells [105,106]\nVaxart Inc Oral recombinant vaccine in tablet formulation using its VAAST platform. It has protected its vaccine tablet formulation by US patent applications [107–109]\nUniversity of Oxford – Jenner Institute ChAD0X1 nCoV-19 – prepared from cold virus (weakened) – initiated Phase III trials [110]\nAltimmune AdCOVID – vaccine delivered via intranasal route platform technologies NasoVAX and NasoShield [111,112]\nMedicago Developing a vaccine and also an antibody. It was successful in producing virus like particles of coronavirus. It is developing antibodies in collaboration with Laval University [113]\nInovio Pharmaceuticals INO-4800 – vaccine that is developed in collaboration with Beijing Advaccinee Biotechnology Company. It is proposing to deliver the vaccine using the device called as CELLECTRA® which works by creating a pulse for transferring the plasmids across the cell. It is also developing INO 4700 in collaboration with GeneOne Life Sciences company [114]\nModerna mRN 1273 – recently received fast track designation from USFDA. It vaccine basically targets spike protein of corona virus [115]\nTonix Pharmaceuticals TNX-1800 – developed based on its horsepox virus vaccine platform. It has filed a provisional patent application with USPTO [116]\nClover Biopharmaceuticals Subunit vaccine developed using trimeric spike protein developed using its patented technology [117]\nNovavax, Inc Middle East Respiratory Syndrome (MERS) vaccine was developed using recombinant nanoparticle based vaccine technology. The vaccine showed positive results in inhibiting the virus when administered along with its patented adjuvant formulations [118–121]\nPredictive oncology (PO) Introduced artificial intelligence for development of a vaccine using Inventa Biotech’s HSCTM technology which deals with chromatographic system of high throughput screening. In addition, PO is also developing a new vaccine based on nanoparticle (NSP-10: non specific protein) platform technology developed by Dr. Daniel Carter [122]"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T7","span":{"begin":2149,"end":2157},"obj":"Phenotype"}],"attributes":[{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Name of the player Details of antiviral vaccines under development Ref.\nMigal Galilee Research Institute, Israel Developing an oral (mucosal) vaccine, wherein the viral antigen is delivered via mucosa tissues by self-activated endocytosis [104]\nEntos Pharmaceuticals Fusogenix – DNA vaccine is being developed based on its patent protected platform, proteo-lipid vehicle (PLV). It uses a new mechanism for delivering genetic material into the cells [105,106]\nVaxart Inc Oral recombinant vaccine in tablet formulation using its VAAST platform. It has protected its vaccine tablet formulation by US patent applications [107–109]\nUniversity of Oxford – Jenner Institute ChAD0X1 nCoV-19 – prepared from cold virus (weakened) – initiated Phase III trials [110]\nAltimmune AdCOVID – vaccine delivered via intranasal route platform technologies NasoVAX and NasoShield [111,112]\nMedicago Developing a vaccine and also an antibody. It was successful in producing virus like particles of coronavirus. It is developing antibodies in collaboration with Laval University [113]\nInovio Pharmaceuticals INO-4800 – vaccine that is developed in collaboration with Beijing Advaccinee Biotechnology Company. It is proposing to deliver the vaccine using the device called as CELLECTRA® which works by creating a pulse for transferring the plasmids across the cell. It is also developing INO 4700 in collaboration with GeneOne Life Sciences company [114]\nModerna mRN 1273 – recently received fast track designation from USFDA. It vaccine basically targets spike protein of corona virus [115]\nTonix Pharmaceuticals TNX-1800 – developed based on its horsepox virus vaccine platform. It has filed a provisional patent application with USPTO [116]\nClover Biopharmaceuticals Subunit vaccine developed using trimeric spike protein developed using its patented technology [117]\nNovavax, Inc Middle East Respiratory Syndrome (MERS) vaccine was developed using recombinant nanoparticle based vaccine technology. The vaccine showed positive results in inhibiting the virus when administered along with its patented adjuvant formulations [118–121]\nPredictive oncology (PO) Introduced artificial intelligence for development of a vaccine using Inventa Biotech’s HSCTM technology which deals with chromatographic system of high throughput screening. In addition, PO is also developing a new vaccine based on nanoparticle (NSP-10: non specific protein) platform technology developed by Dr. Daniel Carter [122]"}

{"project":"LitCovid-sentences","denotations":[{"id":"T172","span":{"begin":0,"end":73},"obj":"Sentence"},{"id":"T173","span":{"begin":74,"end":248},"obj":"Sentence"},{"id":"T174","span":{"begin":249,"end":382},"obj":"Sentence"},{"id":"T175","span":{"begin":383,"end":464},"obj":"Sentence"},{"id":"T176","span":{"begin":465,"end":549},"obj":"Sentence"},{"id":"T177","span":{"begin":550,"end":634},"obj":"Sentence"},{"id":"T178","span":{"begin":635,"end":765},"obj":"Sentence"},{"id":"T179","span":{"begin":766,"end":881},"obj":"Sentence"},{"id":"T180","span":{"begin":882,"end":934},"obj":"Sentence"},{"id":"T181","span":{"begin":935,"end":1002},"obj":"Sentence"},{"id":"T182","span":{"begin":1003,"end":1076},"obj":"Sentence"},{"id":"T183","span":{"begin":1077,"end":1201},"obj":"Sentence"},{"id":"T184","span":{"begin":1202,"end":1357},"obj":"Sentence"},{"id":"T185","span":{"begin":1358,"end":1447},"obj":"Sentence"},{"id":"T186","span":{"begin":1448,"end":1520},"obj":"Sentence"},{"id":"T187","span":{"begin":1521,"end":1586},"obj":"Sentence"},{"id":"T188","span":{"begin":1587,"end":1676},"obj":"Sentence"},{"id":"T189","span":{"begin":1677,"end":1740},"obj":"Sentence"},{"id":"T190","span":{"begin":1741,"end":1869},"obj":"Sentence"},{"id":"T191","span":{"begin":1870,"end":2002},"obj":"Sentence"},{"id":"T192","span":{"begin":2003,"end":2137},"obj":"Sentence"},{"id":"T193","span":{"begin":2138,"end":2338},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Name of the player Details of antiviral vaccines under development Ref.\nMigal Galilee Research Institute, Israel Developing an oral (mucosal) vaccine, wherein the viral antigen is delivered via mucosa tissues by self-activated endocytosis [104]\nEntos Pharmaceuticals Fusogenix – DNA vaccine is being developed based on its patent protected platform, proteo-lipid vehicle (PLV). It uses a new mechanism for delivering genetic material into the cells [105,106]\nVaxart Inc Oral recombinant vaccine in tablet formulation using its VAAST platform. It has protected its vaccine tablet formulation by US patent applications [107–109]\nUniversity of Oxford – Jenner Institute ChAD0X1 nCoV-19 – prepared from cold virus (weakened) – initiated Phase III trials [110]\nAltimmune AdCOVID – vaccine delivered via intranasal route platform technologies NasoVAX and NasoShield [111,112]\nMedicago Developing a vaccine and also an antibody. It was successful in producing virus like particles of coronavirus. It is developing antibodies in collaboration with Laval University [113]\nInovio Pharmaceuticals INO-4800 – vaccine that is developed in collaboration with Beijing Advaccinee Biotechnology Company. It is proposing to deliver the vaccine using the device called as CELLECTRA® which works by creating a pulse for transferring the plasmids across the cell. It is also developing INO 4700 in collaboration with GeneOne Life Sciences company [114]\nModerna mRN 1273 – recently received fast track designation from USFDA. It vaccine basically targets spike protein of corona virus [115]\nTonix Pharmaceuticals TNX-1800 – developed based on its horsepox virus vaccine platform. It has filed a provisional patent application with USPTO [116]\nClover Biopharmaceuticals Subunit vaccine developed using trimeric spike protein developed using its patented technology [117]\nNovavax, Inc Middle East Respiratory Syndrome (MERS) vaccine was developed using recombinant nanoparticle based vaccine technology. The vaccine showed positive results in inhibiting the virus when administered along with its patented adjuvant formulations [118–121]\nPredictive oncology (PO) Introduced artificial intelligence for development of a vaccine using Inventa Biotech’s HSCTM technology which deals with chromatographic system of high throughput screening. In addition, PO is also developing a new vaccine based on nanoparticle (NSP-10: non specific protein) platform technology developed by Dr. Daniel Carter [122]"}